Prostate Cancer Research
Research and Clinical Trials in Prostate Cancer
Prostate cancer clinical trials.
Bone Metastatic Prostate Cancer
Advanced prostate cancer can metastasize to the bone. Once it does, most treatments fail and the patient’s condition can rapidly decline. UC San Diego researchers are working toward a new understanding of what causes prostate cancer to proliferate and become resistant to therapy in the bone microenvironment.
Diet and Cancer Studies
Scientific research indicates that diet substantially affects the risk of contracting certain kinds of cancers, including those of the prostate and bladder. This suggests that diet or dietary constituents may be useful in fighting cancer. UC San Diego urologists, led by J. Kellogg Parsons, MD, are at the forefront of research investigating how diet can be manipulated to potentially prevent and treat genitourinary cancers. Read more.
Men's Eating and Living Study (MEAL) for Prostate Cancer Patients
The Men's Eating and Living Study (MEAL) will help us understand how diet might affect prostate cancer outcome. Read more about MEAL study.
Statins and Prostate Cancer
A study coauthored by Dr. Kane and published in the July 2010 issue of Cancer found that men taking statins are less likely to experience prostate cancer recurrence after radical prostatectomy. Read more on statins and prostate cancer
The primary goal of the Pre-surgical Study Using Neoadjuvant Chemotherapy (PUNCH) is to determine whether treatment with neoadjuvant docetaxel and androgen-deprivation therapy prior to radical prostatectomy will decrease the risk of biochemical recurrence in men with high-risk prostate cancer.
In 2010, the Food and Drug Administration (FDA) approved sipuleucel-T (Provenge), an immunotherapy for androgen-independent prostate cancer. Provenge is designed to provoke the patient’s immune system to target prostate cancer cells. Patients enrolled in the phase 2 Provenge clinical trial at UC San Diego Health System receive sipuleucel-T prior to radical prostatectomy. Biopsy tissue obtained before surgery is compared to the prostatectomy specimen. After radical prostatectomy, patients will be randomly selected to receive either a booster infusion of sipuleucel-T or no further treatment. All study participants will be followed for 72 weeks.